Pfizer (PFE) Stock
Global pharmaceutical company producing medicines and vaccines. Here's the price, business snapshot, and what's worth knowing about Pfizer in September 2026.
Pfizer Inc (PFE) is a large-cap global pharmaceutical company known for developing, producing and commercialising medicines and vaccines across areas such as oncology, immunology, rare disease and infectious disease. The company’s scale, diversified portfolio and R&D pipeline are key considerations for investors: revenue is driven by established products, new approvals and licensing or royalty arrangements. Important risks include regulatory decisions, patent expiries, pricing pressure, competition and litigation — all of which can materially affect earnings. Pfizer has historically returned capital to shareholders via dividends and buybacks, but dividend levels and capital allocation depend on cash flow and strategic priorities. For those researching the stock, focus on upcoming clinical readouts, regulatory milestones, patent timelines, and quarterly financials. This is general educational information, not personal advice; pharmaceutical stocks can be volatile and past performance is not a reliable indicator of future results.
Why It’s Moving
Pfizer is moving on improved guidance, legal relief, and a cautious analyst backdrop.
- Pfizer’s shares are being supported by a combination of better-than-expected quarterly results and a higher revenue outlook, which reassured investors that core operations are stabilizing after a volatile stretch.
- A confidential settlement tied to more than 6,000 Depo-Provera lawsuits eased a major legal overhang, removing one of the key risks hanging over the stock.
- The broader tone remains cautious but constructive: analyst sentiment is still clustered around Hold, while upcoming healthcare conference remarks from CEO Albert Bourla keep attention on pipeline updates and strategic execution.
Pfizer is moving on improved guidance, legal relief, and a cautious analyst backdrop.
- Pfizer’s shares are being supported by a combination of better-than-expected quarterly results and a higher revenue outlook, which reassured investors that core operations are stabilizing after a volatile stretch.
- A confidential settlement tied to more than 6,000 Depo-Provera lawsuits eased a major legal overhang, removing one of the key risks hanging over the stock.
- The broader tone remains cautious but constructive: analyst sentiment is still clustered around Hold, while upcoming healthcare conference remarks from CEO Albert Bourla keep attention on pipeline updates and strategic execution.
Sixth Month Growth Performance
When is the next earnings date for Pfizer (PFE)?
Pfizer’s next earnings date is expected to be November 3, 2026. The report will cover Q3 2026 results. That timing is consistent with Pfizer’s historical early-November earnings pattern.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Pfizer's stock, as it has potential for slight price increase.
Financial Health
Pfizer is showing strong profits and cash flow, reflecting a solid revenue generation capability.
Dividend
Pfizer's high dividend yield of 6.24% makes it appealing for investors seeking income. If you invested $1000 you would be paid $62.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline and innovation
Clinical readouts and regulatory approvals can shift expectations quickly, so investors often watch the pipeline closely — though outcomes can be uncertain.
Key revenue drivers
Vaccines, blockbusters and royalty agreements drive sales, but patent cliffs and pricing pressures can affect future revenue.
Global market reach
Pfizer operates worldwide with diverse market exposure, which can smooth regional volatility but also creates regulatory and geopolitical risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
